Skip to main content

Market Overview

Why NovaBay's Stock Is Trading Lower Today

Why NovaBay's Stock Is Trading Lower Today

NovaBay Pharmaceuticals (NYSE: NBY) shares are trading lower on Tuesday after the company received an FDA warning letter for misleading claims regarding Avenova in COVID-19.

NovaBay Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets anti-infective products for a multitude of uses. It is predominantly focused on commercializing prescription Avenova for the domestic eye care market in the United States. Avenova is the only eye care product formulated with proprietary, stable and pure form of hypochlorous acid (marketed as Neutrox).

The company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. It has partnerships for NeutroPhase in the United States, as well as in other markets.

NovaBay Pharmaceuticals shares were trading down 14.47% at 52 cents on Tuesday. The stock has a 52-week high of $1.94 and a 52-week low of 24 cents.


Related Articles (NBY)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Penny Stocks FDA

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at